NCT06400472 A Study of LY4170156 in Participants With Selected Advanced Solid Tumors Status RECRUITING Phase PHASE1
NCT06395090 A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01) Status WITHDRAWN Phase PHASE1/PHASE2
NCT06393374 Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) Status RECRUITING Phase PHASE3
NCT06391775 Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy Status TERMINATED Phase PHASE1/PHASE2
NCT06389422 Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis Status RECRUITING Phase PHASE2
NCT06385080 A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer Status RECRUITING Phase PHASE1/PHASE2
NCT06384560 Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5) Status RECRUITING Phase PHASE1/PHASE2
NCT06381154 Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer Status RECRUITING Phase PHASE2
NCT06378047 Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer Status COMPLETED Phase PHASE1
NCT06377540 MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma Status RECRUITING Phase PHASE2
NCT06366451 PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC Status RECRUITING Phase EARLY_PHASE1
NCT06357533 Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations Status RECRUITING Phase PHASE3
NCT06356155 Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer Status RECRUITING Phase PHASE2
NCT06353997 Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients Status RECRUITING Phase PHASE2
NCT06353906 Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer Status RECRUITING Phase PHASE2